Drug Profile
Research programme: coronavirus therapeutics - NanoViricides
Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator NanoViricides
- Class Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in COVID-2019-infections in USA
- 09 Jun 2020 NanoViricides Signs Memorandum of Understanding (MoU) with with TheraCour Pharma for research and development of coronavirus therapeutics
- 20 May 2020 NanoViricides plans to request a pre-IND meeting with the US FDA